

# John Maurice Rosenfeld, Ph.D.

33367 Nicholas Common  
Temecula, CA 92592  
619-985-7586 mobile  
jrosenfeld3@roadrunner.com

EMD-Millipore  
28820 Single Oak Drive  
Temecula, CA 92590  
951-216-4619 mobile  
john.rosenfeld@emdmillipore.com

## PROFILE

Life science research and development professional with 23+ years in research and 13+ years commercial experience in scientific management, portfolio management, new product ideation, product development process execution and life cycle management with hundreds of products developed and commercialized. Skilled in scientific networking, technical collaboration, strategic planning, and technology landscaping. Successful track record of team building, staff hiring, development, organizational and program level portfolio management. Pragmatic, creative problem solver with excellent analytical, communication and presentation skills. Valued research and development group leader that has migrated with the business from a startup of twelve to a corporate life science leader of greater than 10,000 people through multiple mergers and acquisitions. Facilitated growth of Epigenetics portfolio by creating and commercializing multi-million dollar research reagent product lines. Flexible and dedicated to achieving business objectives and improving scientific credibility in a competitive sales environment. Initiated development of product lines and customer education strategies that were emulated by multiple competitors. Recipient of 2010 Frost & Sullivan award for market leadership in Epigenetics.

## SKILLS

- Technology Assessment
- Collaboration Management
- Due Diligence
- Budget Administration
- Laboratory Operations
- R&D Collaboration
- Competitor Analysis
- Patent Evaluation
- New Business Initiative & Program Leadership

## PROFESSIONAL EXPERIENCE

### EMD-Millipore Bioscience Division, Temecula, CA 2003-Present

#### 2015-Present: Platform Technology Manager

Responsible for identifying and executing evaluation and licensing of new platform technologies for possible commercialization and product development. Management of licensed technology opportunity pipeline, focusing on innovation profile of license opportunities.

#### 2014-2015: Principal Biologist/Group Leader Assay Development and Platform Technologies

Managed research and development team of seven scientists focused on developing assay products for epigenetics and cancer biology, as well as identifying platform technology opportunities to support innovation strategy in the Nucleic Acid Detection and Core Assays franchises. Responsible for product roadmap development, technology opportunity evaluation and new product introduction selection

#### 2010-2014: Research & Development Manager II, Epigenetics Product Development

Managed research and development team of from five to eight scientists focused on developing assay products for epigenetics, working closely with antibody development and marketing to select targets and provide validation support in epigenetic applications. Co-lead on epigenetics portfolio program, developed assays in areas of chromatin immunoprecipitation, dna methylation detection and non-coding RNA analysis. Developed a technical product development and evaluation process, as well as implemented unique product development process that enabled launch of ~50 kit products annually. Presented externally to drive customer awareness in collaboration with field sales representatives.

**2006-2010: Research & Development Manager II, Chromatin Biology Product Development**

Lead a team of five scientists involved in transferring products from Upstate Biotechnology acquisition into the Temecula site. Included establishing manufacturing and QC processes for lot specific chromatin immunoprecipitation product testing. Product line extended Upstate ChIP kits into Millipore branded Magna ChIP and ChIPab+ product line, as well as supported antibody validation and marketing in building the Millipore epigenetic product portfolio.

**2004-2006: Research & Development Manager I, Gene Regulation**

Managed a group of five scientists involved in developing DNA methylation detection reagents, transcription factor assays, telomerase detection products, and custom OligoDetect molecular pathogen detection assays. Supported transition of molecular products from Serologicals acquisition of InterGen Co. by transferring into Chemicon manufacturing.

**2003-2004: Scientist, Functional Genomics**

Managed custom projects in murine gene targeting of embryonic stem cells using a proprietary knockout technology as a startup company Genome Biosciences, acquired by Chemicon International in 2004. Responsible for project management, knockout and knockin vector construction, validation of gene targeting and genotyping to produce stable cell lines for chimera generation in mouse host.

**Abbott Laboratories, Abbott Park, IL 1989-1990**

Laboratory technician, Retroviral Technical Product Development. Assisted staff in validation of diagnostic ELISAs for HTLVIII/HIV detection

**EDUCATION**

**1998-2003: Salk Institute for Biological Studies, La Jolla, CA**

Post-Doctoral Fellowship in laboratory of Dr. Ronald M. Evans, characterized various orphan nuclear hormone receptors (PPARs, PXR, LXR, FXR) via transgenic animal studies and cell line reporter assays.

**1992-1998: University of California, Irvine, CA**

Ph.D in Molecular Biology and Biochemistry in the laboratory of Dr. Timothy F. Osborne. Thesis involved characterization of an insect homolog of the sterol regulatory element binding protein (HLH106) and delineation of functions of mammalian SREBPs in cell culture models.

**1988-1992: Georgetown University, Washington, D.C.**

B.S. in Biology

**AWARDS & TRAINING**

2010	High Impact Presentations, Dale Carnegie Training
2009	Foundations of Leadership, American Management Association
2005	Leadership Academy, UC Riverside Extension
1999-2001	Postdoctoral Fellowship Recipient, American Heart Association, Western States Affiliate. Identification of PPAR Ligands by In Vivo Ligand Screening
1998-1999	NIH Institutional Training Grant Postdoctoral Fellow Cardiology Training Grant—Ken Chien, M.D., Ph.D. Director
1997	Schneiderman Fellowship for Excellence in Graduate Research
1994-1996	American Heart Association Pre-Doctoral Fellowship Recipient, Western States Affiliate

## PUBLICATIONS

1. Lee CH, Kang K, Mehl IR, Nofsinger R, Alaynick WA, Chong LW, Rosenfeld JM, Evans RM. Peroxisome proliferator-activated receptor delta promotes very low-density lipoprotein-derived fatty acid catabolism in the macrophage. *Proc Natl Acad Sci U S A.* 2006 Feb 14;103(7):2434-9.
2. Saez E, Rosenfeld J, Livolsi A, Olson P, Lombardo E, Nelson M, Banayo E, Cardiff RD, Izpisua-Belmonte JC, Evans RM. PPAR gamma signaling exacerbates mammary gland tumor development. *Genes Dev.* 2004 Mar 1;18(5):528-40.
3. Downes M, Verdecia MA, Roecker AJ, Hughes R, Hogenesch JB, Kast-Woelbern HR, Bowman ME, Ferrer JL, Anisfeld AM, Edwards PA, Rosenfeld JM, Alvarez JG, Noel JP, Nicolaou KC, Evans RM. A chemical, genetic, and structural analysis of the nuclear bile acid receptor FXR. *Mol Cell.* 2003 Apr;11(4):1079-92.
4. Rosenfeld JM, Vargas R Jr, Xie W, Evans RM. Genetic profiling defines the xenobiotic gene network controlled by the nuclear receptor pregnane X receptor. *Mol Endocrinol.* 2003 Jul;17(7):1268-82.
5. Sonoda J, Rosenfeld JM, Evans RM and Xie W. A nuclear receptor-mediated xenobiotic response and its implication in drug metabolism and host protection. *Curr Drug Metab.* 2003 Feb;4(1):59-72. Review.
6. Rosenfeld JM, Kao HK, & Evans RM. Chapter 3. "The Nuclear Receptor Superfamily". *Hormones, Genes and Cancer*, eds. B. Henderson, B. Ponder, R. Ross. Oxford University Press, 2003:38-98.
7. Sonoda J, Xie W, Rosenfeld JM, Barwick JL, Guzelian PS, Evans RM. Regulation of a xenobiotic sulfonation cascade by nuclear pregnane X receptor (PXR). *Proc Natl Acad Sci U S A.* 2002 Oct 15;99(21):13801-6.
8. Chawla A, Lee CH, Barak Y, He W, Rosenfeld J, Liao D, Han J, Kang H, Evans RM. PPARdelta is a very low-density lipoprotein sensor in macrophages. *Proc Natl Acad Sci U S A.* 2003 Feb 4;100(3):1268-73.
9. Bennett MK, Ngo TT, Athanikar JN, Rosenfeld JM. and Osborne TF. Co-stimulation of promoter for low density lipoprotein receptor gene by sterol regulatory element binding protein (SREBP) and Sp1 is specifically disrupted by the Yin Yang 1 (YY1) protein. *J. Biol. Chem.*, 274, 13025-13032, 1999.
10. Rosenfeld JM, Osborne TF. HLH106: A Drosophila Sterol Regulatory Element Binding Protein in a Natural Cholesterol Auxotroph. *J. Biol. Chem.*, 273, 16112-16121, 1998.
11. Osborne TF, Rosenfeld JM. Related Membrane Domains in Proteins of Sterol Sensing and Cell Signaling Provide a Glimpse of Treasures Still Buried Within the Dynamic Realm of Intracellular Metabolic Regulation. *Curr. Op. Lipid.* 9, 137-140, 1998.
12. Lopez JM, Bennet MK, Sanchez HB, Rosenfeld JM. and Osborne TF. Sterol Regulation of Acetyl CoA Carboxylase: A Mechanism for Coordinate Control of Cellular Lipid. *Proc. Natl. Acad. Sci. USA* 93, 1049-1053, 1996.
13. Vallett SM, Sanchez HB, Rosenfeld JM. and Osborne TF. A Direct Role for Sterol Regulatory Element Binding Protein in Activation of 3-hydroxy-3-methylglutaryl CoA Reductase Gene. *J. Biol. Chem.* 271, 12247-12253, 1996.